Navigation Links
Actos Bladder Cancer Lawsuit: Bernstein Liebhard LLP Comments on Outcome of Nation’s Second Actos Lawsuit Trial
Date:9/27/2013

New York, New York (PRWEB) September 27, 2013

The nation’s second trial of an Actos bladder cancer lawsuit (http://www.consumerinjurylawyers.com/actos/Actos-Lawsuit.html) has concluded in Maryland state court, Bernstein Liebhard LLP reports. According to court documents, the jury hearing the case found that Takeda Pharmaceuticals failed to provide proper warnings regarding the association between Actos and bladder cancer to a man who died of the disease last year and awarded his family $1.7 million. But the judge presiding over the Actos lawsuit trial tossed out the verdict in accordance with Maryland law because the jury also found that the decedent’s 30-year smoking habit contributed to the development of the disease. (An v. Nieberlein, 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland.)

“This was a difficult case due to the patient’s medical history. But we are encouraged that the jury agreed with the Plaintiffs’ assertion that Takeda failed to adequately warn patients and doctors about the risk of Actos bladder cancer,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos lawsuit evaluations to individuals who were diagnosed with bladder cancer following long-term use of the drug.

Actos Lawsuits
According to court documents, this is the second time a state court jury has found that Takeda failed to provide proper warnings regarding the association between Actos and bladder cancer. In April, a California Superior Court jury reached similar conclusions and awarded more than $6 million to a man who developed the disease after using Actos for four years. However, that verdict was also set aside after the judge in the case ruled that the Plaintiff’s medical expert had failed to establish that Actos was the specific cause of the man’s bladder cancer. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

The litigation surrounding Actos has been growing since June 2011, when the U.S. Food & Drug Administration (FDA) ordered Takeda to add new warnings to the Actos label, after a study found that long-term use increased the risk for bladder cancer. According to a report from Bloomberg.com, Actos was also pulled from the market in France, while German regulator removed it from the country's list of reimbursed drugs, due to the medication’s association with the disease.*

Court records indicate that thousands of Actos bladder cancer lawsuits are now pending in courts throughout the U.S. This includes more than 2,500 claims that have been filed in a federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana. The first trial in that litigation is scheduled to begin in January. (In re: Actos Product Liability Litigation, MDL No. 2299) According to Bloomberg.com, additional state trials will also get underway in Las Vegas and Chicago in the next several months.*

Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn More about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please call 800-511-5092 today.

*businessweek.com/news/2013-09-26/takeda-failed-to-properly-warn-about-actos-risks-jury-rules-1

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb11172459.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
2. Victim’s Rights to Recover for Actos Bladder Cancer Could Expire Soon
3. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
4. Researchers Offer Explanation for Actos Bladder Cancer Risk
5. New Lawsuit alleges Actos caused Bladder Cancer
6. US Drug Watchdog Now Urges Family Members Of A Diabetic Who Died From Bladder Cancer After Using The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
7. US Drug Watchdog Now Urges Users Of The Diabetes Drug Called Actos To Call The Johnson Law Group if They Have Developed Bladder Cancer-Time Is Of The Essence
8. US Drug Watchdog Now Urges Any US Citizen Who Used the Diabetes Drug Called Actos and Then Developed Bladder Cancer To Contact The Johnson Law Group For A Legal Review
9. US Drug Watchdog Now Urges Loved Ones Of A Diabetic Who Died From Bladder Cancer Who Had Used The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
10. US Drug Watchdog Now Expands Their Efforts to Educate Diabetics About the Diabetes Drug Actos and Bladder Cancer, with the Suggestion Victims Call the Johnson Law Group
11. US Drug Watchdog Now Urges Any Diabetic Who Used the Diabetes Drug Actos and Now Have Been Diagnosed with Bladder Cancer to Call The Johnson Law Group-ASAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: